FY2025 · period end Dec '25 · from the 10-K filed Feb 4, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $3.58B | $3.99B | $4.05B | $4.74B | $8.95B |
| Net Income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B |
| EPS (Diluted) | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $40.56B | $37.76B | $33.08B | $29.21B | $25.43B |
| Total Liabilities | $9.30B | $8.41B | $7.11B | $6.55B | $6.67B |
| Stockholders' Equity | $31.26B | $29.35B | $25.97B | $22.66B | $18.77B |
| Cash & Equivalents | $3.12B | $2.49B | $2.73B | $3.11B | $2.89B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $4.98B | $4.42B | $4.59B | $5.01B | $7.08B |
| Capital Expenditures | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | 0.2% | 0.3% | 0.3% | 0.4% | 0.6% |
| Net Margin | 0.3% | 0.3% | 0.3% | 0.4% | 0.5% |
| Return on Equity | 14.9% | 16.0% | 16.3% | 20.9% | 54.2% |
| Return on Assets | 11.5% | 12.5% | 12.7% | 15.9% | 37.9% |
| Debt / Equity | 0.06× | 0.07× | 0.08× | 0.09× | 0.11× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0001104659-26-080562 | Jul 6, 2026 | Jul 6, 2026 | Jul 6, 2026 11:00 UTC | EDGAR |
| 8-K | 0001104659-26-075127 | Jun 12, 2026 | Jun 17, 2026 | Jun 17, 2026 20:05 UTC | EDGAR |
| 8-K | 0000872589-26-000014 | Apr 29, 2026 | Apr 29, 2026 | Apr 29, 2026 10:50 UTC | EDGAR |
| 10-Q | 0000872589-26-000016 | Mar 31, 2026 | Apr 29, 2026 | Apr 29, 2026 10:54 UTC | EDGAR |
| 8-K | 0001104659-26-040661 | Apr 8, 2026 | Apr 8, 2026 | Apr 8, 2026 11:05 UTC | EDGAR |
| 10-K | 0000872589-26-000008 | Dec 31, 2025 | Feb 4, 2026 | Feb 4, 2026 14:08 UTC | EDGAR |
| 8-K | 0000872589-26-000004 | Jan 30, 2026 | Jan 30, 2026 | Jan 30, 2026 11:51 UTC | EDGAR |
| 8-K | 0001104659-26-002691 | Jan 12, 2026 | Jan 12, 2026 | Jan 12, 2026 11:48 UTC | EDGAR |
Direct links to SEC EDGAR. REGN has additional filings available on the SEC site.
6 numbers REGENERON PHARMACEUTICALS, INC. later changed — same XBRL tag, both filings linked.
Net Cash Provided by (Used in) Operating Activities·Q1 2016
Major restatementwas$29.3M
Revised up in a 10-Q. Any P/OCF built on the original was 34.8% too high.
Revenue from Contract with Customer, Excluding Assessed Tax·Q1 2019
Major restatementwas$1.7B
Revised down in a 10-K. Any P/S built on the original was 24.7% too low.
Revenue from Contract with Customer, Excluding Assessed Tax·Q2 2019
Major restatementwas$1.9B
Revised down in a 10-K. Any P/S built on the original was 22.6% too low.
Net Income (Loss) Attributable to Parent·Q3 2014
Major restatementwas$110.2M
Revised down in a 10-K. Any P/E built on the original was 22.3% too low.
Net Cash Provided by (Used in) Operating Activities·Q1 2015
Major restatementwas-$87.5M
Revised down in a 10-Q.
Revenue from Contract with Customer, Excluding Assessed Tax·Q3 2019
Major restatementwas$2B
Revised down in a 10-K. Any P/S built on the original was 17.5% too low.
REGN is not the only one.
See every restatement we've found across the market — or get an alert the next time REGN revises a number.
Restatements are detected by comparing every vintage of a fact across all of REGENERON PHARMACEUTICALS, INC.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows REGN's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling REGENERON PHARMACEUTICALS, INC. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on REGN yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on REGN and publish the result to your public profile.
Get 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs